PDR001 + Panobinostat for Melanoma and NSCLC

• Status: Withdrawn
• Trial end date: 2022-05-01

Summary

The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer (NSCLC)

• Phase: Phase 1

Details

• Lead Sponsor: Muhammad Furqan
• Collaborator: Novartis Pharmaceuticals
• Treatments: Panobinostat; Spartalizumab